Alvotech and advanz pharma sign commercialization agreement for proposed biosimilar to eylea® ld/hd in europe

Reykjavik, iceland and london, june 18, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma, a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of alvotech's proposed biosimilar to eylea® (aflibercept). alvotech is currently developing avt06, a proposed biosimilar to eylea® low dose (2 mg) and avt29, a biosimilar candidate for eylea® high dose (8 mg).
ALVO Ratings Summary
ALVO Quant Ranking